{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-022800","form_type":"8-K/A","ticker":"OBIO","cik":"0001814114","company_name":"Orchestra BioMed Holdings, Inc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.709275+00:00","generated_at":"2026-06-17T16:59:09.593360+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Orchestra BioMed reports 2022 net loss of $33.6M; revenue up to $3.5M from negative prior year","bullets":["Net loss was $33.6M for 2022 vs $23.0M in 2021; operating expenses rose to $36.2M.","Revenue of $3.5M included $2.9M partnership revenue; product revenue flat at $0.7M.","Cash and marketable securities totaled $83.7M at Dec 31, 2022, up from $9.9M; funded by Series D preferred stock.","Accumulated deficit reached $199.7M; management expects continued losses but has sufficient liquidity post-merger.","Business combination with HSAC2 (SPAC) closed Jan 2023; audited financials now filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-022800","json":"https://secwatch.observer/filing/0001213900-23-022800.json","markdown":"https://secwatch.observer/filing/0001213900-23-022800.md","text":"https://secwatch.observer/filing/0001213900-23-022800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023022800/0001213900-23-022800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023022800/ea175559-8ka1_orchestra.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T16:59:09.593360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"857a4a379ab9f1362a453df9c4637e3abd1316e9","claim":"Orchestra BioMed Holdings, Inc. reported financial results for the fiscal year ended December 31, 2022.","evidence_excerpt":"Item 2.02. Results of Operations and Financial Condition. The financial statements set forth under paragraph (a)(1) of Item 9.01 of this Current Report on Form 8-K are incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1814114/000121390023022800/0001213900-23-022800-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}